Insulet is delivering strong Omnipod-driven growth, with Q1 revenue up 33.9% and guidance raised for 2026. The stock looks attractive for growth investors, but its premium valuation and execution risk keep the case from being low-risk.
Insulet Corporation (PODD) combines unusually strong growth with a defensible recurring-revenue model, but the stock still carries a premium valuation and meaningful execution risk. Q1 2026 revenue reached $761.7M, up 33.9% year over year, while adjusted EPS rose 39.7% to $1.42. Management also raised full-year 2026 revenue growth guidance to 21% to 23% and maintained a forecast for adjusted EPS growth above 25%.
The investment case rests on three facts: Omnipod 5 is expanding in both the U.S. and international markets, 85% of U.S. new customer starts came from multiple daily injection therapy in Q1, and analysts estimate EPS will rise to $8.05 in 2027 from trailing EPS of $4.28. That combination gives Insulet a long runway for conversion, product upgrades, and operating leverage.
The counterweight is valuation. At a quoted price of $165.00, PODD trades at 39.0x trailing earnings, 26.6x forward earnings, and 1.5x PEG. The balance of growth, cash generation, and valuation supports a Buy recommendation for a moderate-risk investor with a medium-term horizon, but not an assumption that every future product launch will land perfectly.
Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company was incorporated in 2000, is headquartered in Acton, Massachusetts, employs approximately 5,400 people, and trades on NASDAQ under PODD.
The Omnipod platform includes Omnipod 5, Omnipod DASH, and the Classic Omnipod system. Omnipod 5 is the strategic center of the business because it combines a disposable tubeless pod, automated insulin delivery software, continuous glucose monitor connectivity, and smartphone control.
Insulet's business is overwhelmingly driven by Omnipod. In Q1 2026, total Omnipod revenue was $758.4M, compared with $3.3M from Drug Delivery. The concentration creates operating focus and recurring demand, while also making product reliability and Omnipod 5 adoption central to the entire investment case.
The U.S. Omnipod business generated $515.6M in Q1 revenue, up 28.3% year over year. International Omnipod revenue reached $242.9M, up 59.4% on a reported basis and 45.2% in constant currency. International growth is therefore running faster than the U.S. business, although management expects the pace to moderate as prior product launches become harder comparisons.
The sales model is also distinctive. Insulet sells primarily through the pharmacy channel in the United States, reducing the upfront equipment burden associated with traditional durable medical equipment. The 2025 10-K reported that 86% of global Omnipod product sales moved through intermediaries, with three distributors representing 27%, 26%, and 25% of total revenue.
That distributor concentration is a commercial strength and a risk. It gives Insulet efficient reach, but a change in reimbursement terms, formulary access, or distributor relationships could affect revenue and margins across a concentrated platform.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Omnipod 5 is a disposable, tubeless automated insulin delivery system. The pod can be worn for up to three days, placed on the abdomen, hip, back of the upper arm, upper thigh, or lower back, and used in water up to 25 feet for 60 minutes under its IP28 rating.
The system embeds Insulet's proprietary automated insulin delivery algorithm in the pod and receives glucose readings from a connected continuous glucose monitor through Bluetooth. Users can control the system through an Insulet handheld device or smartphone apps. Omnipod 5 currently integrates with Dexcom G6 and G7 sensors and Abbott's FreeStyle Libre 2 Plus in selected markets.
Product migration is progressing. In Q1, 95% of the U.S. customer base used Omnipod 5, compared with 65% internationally. The international gap creates a conversion opportunity because customers moving from DASH to Omnipod 5 generate favorable price and product mix.
The product's commercial value is not limited to hardware. A three-day disposable pod, smartphone control, automated dosing, and integration with multiple sensors reduce several points of friction that have historically limited pump adoption. The result is a consumables model in which a successful customer start can produce repeat pod demand rather than a one-time equipment sale.
Insulet's competitive advantage is built from product design, software, access, brand, and manufacturing scale. More than 1,000 issued patents and over 700 pending patent applications covered the Omnipod drive system, cannula insertion, algorithms, apps, user interfaces, and future product generations as of December 31, 2025.
The 2026 algorithm update adds a 100 mg/dL target glucose option. Management said simulated analysis showed an approximately 5% improvement in time in range from the target change, while additional software changes are designed to keep users in automated mode longer during extended high-glucose events.
Sensor interoperability is another advantage. Insulet's U.S. Libre 3 Plus integration expands access to Omnipod 5 for nearly 450,000 people using that sensor, according to management. The company also plans to launch Omnipod 6 with a third-generation algorithm in 2027.
The type 2 pipeline adds longer-term optionality. A feasibility study for a fully closed-loop type 2 system produced 68% time in range with no boluses, and Insulet enrolled the first participant in the EVOLVE pivotal study. Management plans a 2028 launch for that product. These milestones support the growth thesis, but they also place regulatory, clinical, and commercial execution on the critical path.
Insulet manufactures products at highly automated facilities in Acton, Massachusetts, and Johor, Malaysia. The company is investing in a third facility in Costa Rica and also uses manufacturing lines at a contract facility in China. Management said the Costa Rica site is expected to go live in 2029.
Disposable electromechanical devices require high-volume production, tight quality controls, and dependable component sourcing. Insulet relies on external suppliers for application-specific integrated circuits, Bluetooth chips, and other specialized parts. Some components are sole-sourced because of proprietary designs, regulatory requirements, or limited supplier capacity.
The company manages sole-source exposure through inventory held internally and at suppliers, but this does not eliminate disruption risk. Insulet also executed a voluntary medical device correction in March 2026 and implemented targeted manufacturing fixes. The event reinforces a basic medtech rule: growth is valuable only when quality keeps pace.
Q1 adjusted gross margin was 71.0%, despite more than 150 basis points of pressure from excess and obsolescence costs during pod configuration changes. Management attributed the underlying margin performance to manufacturing productivity, strong revenue growth, and positive pricing.
Insulet operates in a diabetes device market shifting from standalone pumps toward integrated automated insulin delivery ecosystems. These ecosystems combine a continuous glucose monitor, pump, dosing algorithm, smartphone control, and analytics. The shift favors companies that can coordinate hardware, software, clinical evidence, and reimbursement.
Insulet estimates that approximately 6 million people have type 1 diabetes in the countries it serves. It also estimates approximately 6 million people have insulin-requiring type 2 diabetes in those countries, with another 3 million U.S. type 2 patients requiring basal insulin only. Pump adoption remains a minority of these populations.
The broader medical device market is estimated by MarketsandMarkets to grow from $637.4B in 2026 to $829.7B in 2031, a 5.4% compound annual growth rate. Wireless medical devices are estimated by Mordor Intelligence to grow at a 12.1% compound annual rate from 2025 to 2030. Insulet's Q1 growth of 33.9% shows that its AID category is expanding faster than the broad equipment market.
The most important market opportunity is conversion from multiple daily injections. In Q1, 85% of U.S. new customer starts came from MDI. That fact matters more than a broad theoretical market estimate because it identifies the actual source of current customer additions.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Insulet serves people with type 1 diabetes, insulin-requiring type 2 diabetes, caregivers, physicians, payers, and pharmacy distributors. More than 600,000 estimated active Omnipod users were reported globally as of December 31, 2025, and the Q1 2026 global customer base grew nearly 25% year over year.
The customer journey often starts with an MDI user seeking fewer injections, more flexible dosing, or better glucose control. Omnipod's tubeless design addresses the physical burden of tubing, while automated dosing and smartphone control address daily management complexity.
Payer access is central to conversion. Insulet reported U.S. coverage above 90% and a 4% net access improvement in Q1 that benefited an additional 16 million lives. In Canada, reimbursement approval covered 85% of the market. These figures support the commercial case, although reimbursement negotiations remain a permanent feature of the business.
Retention deserves equal attention. Management expects retention to decrease modestly as the type 2 customer base grows and is investing in onboarding, engagement, and long-term retention programs. That comment signals that rapid customer acquisition can carry a different retention profile from the established type 1 base.
Insulet competes directly with Medtronic and Tandem Diabetes Care in insulin pumps, as well as Beta Bionics, mylife Diabetes Care, and Sequel Med Tech. The company also competes indirectly with insulin pens, smart pens, syringes, and medication-based approaches to type 2 diabetes.
Insulet's clearest hardware distinction is the tubeless, disposable pod. Medtronic and Tandem primarily offer durable pump systems with tubing, while Beta Bionics' iLet emphasizes simplified automated insulin delivery. Each competitor can challenge Insulet through algorithm performance, sensor integration, clinical evidence, price, or payer relationships.
Competition is not automatically negative. Management said growing competition is raising awareness of AID and Omnipod, which can expand the category. The more important test is whether Insulet keeps its lead in new customer starts, product interoperability, clinical outcomes, and pharmacy access.
The 10-K describes the diabetes device market as highly competitive and subject to rapid product change. That assessment makes product cadence a valuation issue, not just an engineering issue. A premium multiple requires Insulet to keep converting new users while maintaining quality and customer loyalty.
The macro backdrop is mixed. Diabetes care benefits from chronic demand, while healthcare providers and payers continue to manage cost pressure. Insulet's pharmacy-channel model can reduce upfront equipment costs, but payer contracts and reimbursement decisions still influence adoption.
Foreign exchange is material because international Omnipod revenue grew 59.4% on a reported basis versus 45.2% in constant currency in Q1. Management expects foreign currency to provide approximately 100 basis points of benefit to full-year 2026 growth, so reported growth will not be a pure measure of underlying demand.
Geopolitical risk is already entering the outlook. Management cited incremental raw material and shipping costs related to the ongoing conflict in the Middle East. These costs are being absorbed alongside higher capital spending for global manufacturing expansion.
Regulation is another structural macro factor. Omnipod products require FDA clearance or approval, clinical evidence where applicable, quality-system compliance, post-market reporting, and ongoing oversight. GLP-1 medicines also form part of the competitive backdrop because they can delay progression to insulin therapy for some type 2 patients.
Insulet’s A- balance sheet reflects a solid financial position that supports growth investment, but the report still flags the need to manage execution carefully as the business scales.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue jumped 33.9% to $761.7M and adjusted EPS rose 39.7% to $1.42, showing strong operating momentum in the core Omnipod franchise.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 revenue growth guidance to 21% to 23% and kept adjusted EPS growth above 25%, while analysts see EPS reaching $8.05 in 2027 from $4.28 trailing.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $165.00, PODD trades at 39.0x trailing earnings, 26.6x forward earnings, and 1.5x PEG, leaving valuation as the main constraint on the bull case.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s $220 fair value sits above the current price and reflects a Buy stance, with upside tied to Omnipod adoption and operating leverage.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Insulet has built one of the stronger growth profiles in medical devices. Q1 2026 combined $761.7M of revenue, 33.9% year-over-year growth, a 17.5% adjusted operating margin, and $1.42 of adjusted EPS. The U.S. and international businesses are both growing, while Omnipod 5 conversion, Libre 3 Plus compatibility, Omnipod 6, and the type 2 pipeline extend the product runway.
The balance sheet is capable of funding expansion, with a 2.78 current ratio, 0.63 debt-to-equity ratio, $500M of available credit, and positive free cash flow. The main risks are concentrated revenue exposure, distributor dependence, medical device quality, international execution, reimbursement, and the cash impact of share repurchases and capacity investment.
At $165.00, the stock offers a favorable medium-term setup for investors who value growth and recurring revenue but can tolerate a premium multiple. A Buy rating is appropriate because the operating evidence is strong enough to outweigh the valuation risk, while the $220.00 central target leaves room for setbacks that a more aggressive target would ignore.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Insulet beat on EPS and revenue, lifted full-year guidance, and still saw PODD drop sharply. This deep-dive looks beyond the headline beat to examine Omnipod growth, margin expansion, guidance nuance, and why investors focused on valuation and reaction rather than the strong quarter.
Insulet is compounding revenue, margins, and free cash flow while expanding Omnipod’s reach in type 1 and type 2 diabetes. The stock still trades at a premium, but the growth runway and product leadership remain compelling.
Insulet Corporation (PODD) drops 6.3% even after earnings beats, as investors react to the latest quarterly results and outlook.